Metformin shown to prevent long COVID across risk groups in multiple randomized trials

Multiple randomized clinical trials and electronic health record studies now show that metformin, a widely used and well-established medication, significantly reduces the risk of developing long COVID when taken during or shortly after acute infection with SARS-CoV-2. The findings are published in Clinical Infectious Diseases.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup